Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
[HTML][HTML] PD-1/PD-L1 pathway: current researches in cancer
Y Han, D Liu, L Li - American journal of cancer research, 2020 - ncbi.nlm.nih.gov
Cancer immunotherapy has been accompanied by promising results over the past few
years. Programmed Cell Death Protein 1 (PD-1) plays a vital role in inhibiting immune …
years. Programmed Cell Death Protein 1 (PD-1) plays a vital role in inhibiting immune …
Regulation and function of the PD-L1 checkpoint
Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
Mechanisms regulating PD-L1 expression on tumor and immune cells
S Chen, GA Crabill, TS Pritchard, TL McMiller… - … for immunotherapy of …, 2019 - Springer
Abstract Background The PD-1/PD-L1 checkpoint is a central mediator of
immunosuppression in the tumor immune microenvironment (TME) and is primarily …
immunosuppression in the tumor immune microenvironment (TME) and is primarily …
PD-L1 distribution and perspective for cancer immunotherapy—blockade, knockdown, or inhibition
Cancer immunotherapy involves blocking the interactions between the PD-1/PD-L1 immune
checkpoints with antibodies. This has shown unprecedented positive outcomes in clinics …
checkpoints with antibodies. This has shown unprecedented positive outcomes in clinics …
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Inhibitors of VEGF (vascular endothelial growth factor)/VEGFR2 (vascular endothelial growth
factor receptor 2) are commonly used in the clinic, but their beneficial effects are only …
factor receptor 2) are commonly used in the clinic, but their beneficial effects are only …
Deubiquitination and stabilization of PD-L1 by CSN5
Pro-inflammatory cytokines produced in the tumor microenvironment lead to eradication of
anti-tumor immunity and enhanced tumor cell survival. In the current study, we identified …
anti-tumor immunity and enhanced tumor cell survival. In the current study, we identified …
Regulation of PD-L1 Expression by NF-κB in Cancer
F Antonangeli, A Natalini, MC Garassino… - Frontiers in …, 2020 - frontiersin.org
Immune checkpoints are inhibitory receptor/ligand pairs regulating immunity that are
exploited as key targets of anti-cancer therapy. Although the PD-1/PD-L1 pair is one of the …
exploited as key targets of anti-cancer therapy. Although the PD-1/PD-L1 pair is one of the …
[HTML][HTML] Regulation of PD-L1: a novel role of pro-survival signalling in cancer
Evasion of immune system is a hallmark of cancer, which enables cancer cells to escape the
attack from immune cells. Cancer cells can express many immune inhibitory signalling …
attack from immune cells. Cancer cells can express many immune inhibitory signalling …
The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment
K Hudson, N Cross, N Jordan-Mahy… - Frontiers in …, 2020 - frontiersin.org
Programmed death-ligand 1 (PD-L1) is an immune checkpoint inhibitor that binds to its
receptor PD-1 expressed by T cells and other immune cells to regulate immune responses; …
receptor PD-1 expressed by T cells and other immune cells to regulate immune responses; …